Crism Therapeutics annual free cash flow
2023
2024
2025
Crism Therapeutics Free Cash Flow (FCF) History (CRTX)
Crism Therapeutics reported −£2.0M in free cash flow for fiscal 2025, a decrease of £1.0M from the previous fiscal year, with a free cash flow margin of −864.94%.
View full Crism Therapeutics company overviewCrism Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −£2.0M | −£1.0M | — | −864.94% |
| 2024 | 2024-12-31 | −£961,000 | −£851,000 | — | −3844.00% |
| 2023 | 2023-12-31 | −£110,000 | — | — | −244.44% |
Crism Therapeutics free cash flow growth trends
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Crism Therapeutics source filings ↗Community posts
CRISM reports higher development spending and a £1.41 million loss
CRISM Therapeutics ($CRTX) reported a first-half loss of £1.413 million, compared with £0.930 million a year earlier. Administrative expenses reached £1.52 million, including £956,000 of research and development spending. Operating cash out ...
